HS
ACHN

HighVista Strategies’s Achillion Pharmaceuticals ACHN Stock Holding History

HighVista Strategies’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,800
Closed -$53K – 153
2019
Q3 		$53K Buy
+14,800
New +$57.1K 0.04% 121

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighVista Strategies's ACHN Position: Q4 2019 in Review

HighVista Strategies sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 14,800 shares — an estimated $53K sold.

HighVista Strategies first reported a position in ACHN in Q3 2019 and held it in 1 quarter. The position peaked at $53K in Q3 2019. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • HighVista Strategies reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • HighVista Strategies sold 14,800 Achillion Pharmaceuticals shares in Q4 2019, an estimated $53K.
  • HighVista Strategies first reported a position in Achillion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • HighVista Strategies's Achillion Pharmaceuticals position peaked at $53K in Q3 2019.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on HighVista Strategies's 13F filing for Q4 2019, filed 14 Feb 2020.